Wnt Signaling Pathway Modulation in Cancer Mechanisms

The Wnt signalling pathway governs key processes in embryonic development, tissue homeostasis and stem cell maintenance by regulating gene expression through β-catenin–dependent and β-catenin–independent cascades. In cancer, aberrant activation or suppression of Wnt components contributes to uncontrolled proliferation, invasion and resistance to therapy. Mutations in receptors, co‐receptors and downstream effectors such as adenomatous polyposis coli (APC) and β-catenin are frequent in colorectal, hepatocellular and pancreatic malignancies. Beyond genetic alterations, dynamic modulation of Wnt receptor abundance at the cell surface—via ubiquitylation, endocytosis and deubiquitylation—emerges as a critical mechanism by which tumours fine‐tune signal strength. Crosstalk with MAPK, PI3K–AKT and JAK–STAT pathways further amplifies oncogenic programmes and shapes the tumour microenvironment. Recent efforts target ligand–receptor interfaces, signalosome assembly and downstream transcriptional regulators to restore homeostatic control or exploit pathway dependence. Small molecules, neutralising antibodies and proteolysis-targeting chimeras (PROTACs) demonstrate proof of principle in preclinical models, underscoring global significance for precision oncology. As understanding deepens of tissue- and context-specific modulation, therapeutic strategies are increasingly poised to disrupt Wnt-driven tumourigenesis while sparing normal stem cell functions.

Research from Nature Portfolio

Recent work has identified a deubiquitylating enzyme complex—comprising USP46, UAF1 and WDR20—as a positive regulator of Wnt/β-catenin signalling. The complex binds the Wnt co-receptor LRP6 upon pathway activation, removes sterically hindering ubiquitin chains and stabilises surface receptor levels. Loss of the USP46 complex reduces LRP6 abundance, attenuates Wnt target‐gene expression and compromises viability of intestinal organoids in culture and in vivo. This mechanism highlights dynamic control of receptor homeostasis as a central node in tumour-associated Wnt modulation and suggests deubiquitylases as potential drug targets to recalibrate aberrant signalling in cancer.

Wnt Signaling Pathway Modulation in Cancer Mechanisms publication trend

The graph below shows the total number of articles in wnt signaling pathway modulation in cancer mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Wnt signalling pathway: A network of secreted glycoproteins, receptors and co-receptors that regulates gene transcription via β-catenin-dependent (canonical) and β-catenin-independent (non-canonical) routes.

β-catenin: A cytoplasmic protein that, upon stabilisation, translocates to the nucleus to activate Wnt target genes in complex with T-cell factor/lymphoid enhancer factor.

LRP6: Low-density lipoprotein receptor-related protein 6, a coreceptor essential for propagation of canonical Wnt signals at the cell surface.

Ubiquitylation: Post-translational attachment of ubiquitin to lysine residues on target proteins, often marking them for proteasomal degradation or altering their cellular trafficking.

Deubiquitylation: Enzymatic removal of ubiquitin chains by deubiquitylases, rescuing proteins from degradation and modulating signal transduction.

RNF43: A RING-type E3 ubiquitin ligase that downregulates Wnt signalling by promoting ubiquitylation and internalisation of Wnt receptors.

USP46 complex: A trimeric deubiquitylase assembly (USP46, UAF1, WDR20) that stabilises LRP6 and enhances Wnt/β-catenin activity.

DKK1: Dickkopf-1, a secreted Wnt pathway antagonist that disrupts ligand–receptor interactions and modulates the tumour microenvironment.

References

1. The USP46 complex deubiquitylates LRP6 to promote Wnt/β-catenin signaling. Nature Communications (2023).
2. RNF43 Inactivation Enhances the B‐RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells. Advanced Science (2024).
3. Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions. Experimental Hematology & Oncology (2025).